PSA screening leads to overdiagnosis, study saysReports on a study which argued that prostate specific antigen (PSA) testing for prostate cancer leads to overdiagnosis. Indication that many men diagnosed with prostate cancer would have died from another cause; Significant morbidity associated with the ...
但是,也有研究显示,PSA筛查并不能降低前列腺癌的死亡率,如英国前列腺癌PSA检测的整群随机试验和美国前列腺、肺、结肠和卵巢癌筛查试验(the prostate,lung,colorectal and ovarian cancer screening trial,PLCO)。造成上述研究结果不一致的...
1 additional high-grade cancer per 196 men and 1 low-grade cancer per 909 men were detected among those randomized to be invited to undergo a single prostate cancer screening intervention compared with those not invited to ...
Screening: PSA screening reduced mortality from prostate cancer. Nature Reviews Clinical Oncology 9 , 249-249 /Screening:PSA screening reduced mortality from prostate cancer. Nat Rev Clin Oncol . 2012Screening: PSA screening reduced mortality from prostate cancer. Nat Rev Clin Oncol 2012;9:249....
The PSA screening blood test measures the levels of PSA circulating in the blood. Both normal prostate cells and cancer cells make PSA. While prostate cancer cells tend to produce less PSA than normal cells, they allow PSA to more easily pass through the cell wall and eventually wind up in...
MRI 资源，并减少了1和2组前列腺的过度诊断MRI 的最佳 PSA 截断值目前还不清楚 原文阅读：https://www.urotoday.com/conference-highlights/eau-2024/eau-2024-prostate-cancer/151073-eau-2024-risk-adapted-screening-for-prostate-cancer-in-europe-psa-mri-opt-the-swedish-nationwide-screening-strategy.html ...
The aim of screening for prostate cancer is to detect malignancy at an early and potentially treatable stage, thereby increasing the chance of cure. Although serum PSA has been used as a screening test for prostate cancer for over 20 years, the practice is controversial. As a screening test ...
and PCa+ Treatment PSA Screening and PCa+ TreatmentPSA Screening and PCa+ TreatmentMayo Clinic Reviews in Urology 2014 - Current state of PSA screening and PCa treatment Anthony V. D'Amico, MD, PhDJennifer Bennett
Digital rectal examination in prostate cancer screening at PSA level 3.0-3.9 ng/ml: long-term results from a randomized trial for free/total PSA, and the specificity 0.91 (95% CI 0.88–0.93, 419/461) for DRE and 0.85 (95% CI 0.78–0.90, 134/158) for free/total PSA... V Soronen...
According to Schlegel, early screening is the only way to stop prostate cancer since there are no curative treatments once the disease spreads. "There will be more people who die of prostate cancer because of the application of these study results," he said. ...